Hospital

Minimizing sedation, cognitive impairment, and addiction risk are key priorities.

Rapid insulin discontinuation occurred with tirzepatide 2.5 mg weekly in long-standing type 2 diabetes, demonstrating a low-dose responder phenotype and pharmacist-led CGM-guided deprescribing.

FDA approval clears interchangeable golimumab biosimilars for rheumatoid arthritis and ulcerative colitis, promising lower-cost TNF therapy.

Six-year follow-up data from the SEQUOIA trial showed that zanubrutinib provided durable PFS and strong long-term outcomes in treatment-naïve CLL/SLL.

Pharmacists lead antifungal and antibiotic stewardship beyond hospitals, using rapid diagnostics, vaccines, and equity to curb resistance.

Pharmacists must balance the lifesaving automation of advanced technology with the harsh reality of a high-cost, high-risk transition.

Darren Triller, PharmD, walks through the relative ease and impact of each of the 5 ADAPT priority areas, makes the case for dashboard-driven population health management.

Clinical pharmacists Andrew Willeford and Laura Velazquez explore the paradigm shift in oHCM management, highlighting best practices for pharmacist-led clinical workflows in health-system practice.

Neoadjuvant pembrolizumab in colorectal cancer delivers durable, relapse-free outcomes presurgery, with ctDNA blood tests helping to predict responders.

A single dose of psilocybin produced rapid and clinically meaningful reductions in depressive symptoms in patients with major depressive disorder.

Laughing gas misuse is surging as nitrous oxide drug abuse spreads online

Phase 3 SCORPIO-PEP trial shows ensitrelvir cuts symptomatic COVID-19 after household exposure, boosting postexposure prophylaxis options for high-risk patients.

This week’s episode covers Marty Makary’s resignation as FDA commissioner, evolving hepatitis B vaccination efforts, and new FDA approvals in asthma and precision oncology.

Neurology pharmacists drive safer medication changes, boost access and financial assistance, and deliver major cost savings through high-impact outpatient pharmacist intervention.

HBV still threatens health workers as vaccination programs stall; learn how managers and pharmacists can boost coverage with digital tracking.

Securing executive buy-in, building multidisciplinary coalitions, and targeting inappropriate antiplatelet use are among the most critical steps in implementing antithrombotic stewardship programs.

Data from a phase 1/2 trial revealed that CRISPR–Cas9–edited donor stem cell transplants lacking CD33 enabled rapid engraftment and allowed posttransplant gemtuzumab ozogamicin maintenance in high-risk patients with AML/MDS without prolonged hematologic toxicity.

A novel urine-based test outperformed mpMRI in detecting prostate cancer progression and may help reduce unnecessary biopsies.

Emerging evidence supports the use of psilocybin in palliative care, yet Schedule I status uniquely limits access outside of clinical trials in the US.

FDA approval brings the first all-oral AML combination therapy, decitabine/cedazuridine with venetoclax, for older or unfit patients, cutting clinic visits.

Phase 1b data show zongertinib delivers durable first-line responses in HER2-mutant NSCLC, including brain metastases, with manageable safety.

The commissioner's sudden departure leaves the agency navigating a crowded agenda of unresolved policy questions—many with direct implications for pharmacists and their patients.

Newborn vitamin K shot refusals rise, boosting bleeding risk; learn neonatal safety facts and how the vitamin K shot prevents deadly VKDB.

As medetomidine rapidly displaces xylazine as a fentanyl adulterant, pharmacists must recognize its distinct toxidrome, understand why naloxone alone is insufficient, and support updated harm reduction strategies in an increasingly complex overdose landscape.

Pharmacy Times interviews Benjamin Kematick, PhD, BCACP, BCPMP, and explores the safety profile of Levorphanol compared with methadone, including potential reductions in risks such as accumulation, QT prolongation, and drug interactions, as well as its implications for clinical workflows and the pharmacist’s role in supporting safe opioid rotation, monitoring, and patient counseling.

Darren Triller, PharmD, makes the case for system-level solutions over individual clinical effort, introducing the ADAPT framework

Pharmacy Times interviews Benjamin Kematick, PhD, BCACP, BCPMP, and examines how levorphanol compares to methadone in pharmacology and clinical efficacy, as well as the key evidence supporting its use and the practical barriers clinicians face when transitioning between the two agents in complex pain management.

A new JAMA study links GLP-1s like Wegovy, Ozempic, Zepbound, and Mounjaro to better breast cancer survival, lower recurrence, and weight loss benefits.